We showed that HELDR promotes EGFR-driven GBM tumorigenesis by inducing genes in oncogenic pathways critical for GBM malignancy via binding to and recruiting p300 to KAT7 gene promoter independent of EGFR expression and signaling. Here, KAT7 is linked to glioblastoma.